The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Open accessAbstract
BACKGROUND: Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In phase 2 studies involving patients with chronic kidney disease, roxadustat increased levels of endogenous erythropoietin to within or near the physiologic range, along with increasing hemoglobin levels and improving iron homeostasis. Additional data are needed regarding the efficacy and safety of roxadustat for the treatment of anemia in patients with chronic kidney disease who are not undergoing dialysis. METHODS: In this phase 3 trial conducted at 29 sites in China, we randomly assigned 154 patients with chronic kidney disease in a 2:1 ratio to receive roxadustat or placebo three times a week for 8 weeks in a double-blind manner. All the patients had a hemoglobin level of 7.0 to 10.0 g per deciliter at baseline. The randomized phase of the trial was followed by an 18-week open-label period in which all the patients received roxadustat; parenteral iron was withheld. The primary end point was the mean change from baseline in the hemoglobin level, averaged over weeks 7 through 9. RESULTS: During the primary-analysis period, the mean (±SD) change from baseline in the hemoglobin level was an increase of 1.9±1.2 g per deciliter in the roxadustat group and a decrease of 0.4±0.8 g per deciliter in the placebo group (P<0.001). The mean reduction from baseline in the hepcidin level (associated with greater iron availability) was 56.14±63.40 ng per milliliter in the roxadustat group and 15.10±48.06 ng per milliliter in the placebo group. The reduction from baseline in the total cholesterol level was 40.6 mg per deciliter in the roxadustat group and 7.7 mg per deciliter in the placebo group. Hyperkalemia and metabolic acidosis occurred more frequently in the roxadustat group than in the placebo group. The efficacy of roxadustat in hemoglobin correction and maintenance was maintained during the 18-week open-label period. CONCLUSIONS: In Chinese patients with chronic kidney disease who were not undergoing dialysis, those in the roxadustat group had a higher mean hemoglobin level than those in the placebo group after 8 weeks. During the 18-week open-label phase of the trial, roxadustat was associated with continued efficacy. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652819.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prolyl hydroxylase inhibitors or HIF stabilizers, now tested in chronic kidney disease, by increasing HIF-2α might target two abnormal processes enhancing both erythropoietin synthesis and iron absorption.134”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Self-citationPrevalence of chronic kidney disease in China: a cross-sectional survey
Zhang, L., Wang, F., Wang, L., Wang, W., Liu, B., Liu, J., Chen, M., He, Q., Liao, Y., Yu, X., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60033-6 · Cited by 2,104
Self-citationA trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,094
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Regulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
Peyssonnaux, C., Zinkernagel, A. S., Schuepbach, R. A., Rankin, E., Vaulont, S., Haase, V. H., Nizet, V., & Johnson, R. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31370 · Cited by 639
Flagged first, then by citations
Research works printed but not linked: 3
- Zhu LN, Lv W, Teng J, et al. Association of residual renal function at initiation of dialysis with prognosis in maintenance dialysis patients. Chin J Nephrol 2012:757-764.
- Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18:Suppl 2:ii2-ii6.12819293
- KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3(1):1-150 (https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf).
Cited by
Sorted by citations
Items 501–584 of 584
Management of Anemia in Peritoneal Dialysis Patients
Gupta, N., & Wish, J. B. (2022) · Springer eBooks · doi:10.1007/978-3-319-90760-4_45-1
The Mechanism of HIF-PHI in the Treatment of Renal Anemia and the Research Progress of Roxadustat
王, 加. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.126853
Yamazaki, T., Mimura, I., Miura, R., Sato, D., Kurata, Y., Tanaka, T., & Nangaku, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1961344/v1
Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk
Harlow, C. E., Patel, V. V., Waterworth, D. M., Wood, A. R., Beaumont, R. N., Ruth, K. S., Tyrrell, J., Oguro‐Ando, A., Chu, A. Y., & Frayling, T. M. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac215
Efficacy of HIF-PH inhibitors in the treatment for renal anemia
坂下, 碧., & 南学, 正. (2022) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.59.263
Xu, C., Luo, D.-G., Liu, Z.-Y., Yang, D. H., Wang, D., Xu, Y.-Z., Yang, J. J., Fu, B., & Qi, A. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i35.13122
Self-citationAniort, J., Grèze, C., & Kosmadakis, G. (2022) · Néphrologie & Thérapeutique · doi:10.1016/s1769-7255(22)00650-2
Stabilisation of HIF signalling extends epicardial activation and neonatal heart regenerationPreprint
Gamen, E., Price, E., Pezzolla, D., Villiers, C. D., Rohling, M., Sayers, J., Silva, C. R., Sun, X., Salama, R. A., Mole, D. R., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2496938/v1
Yang, C., Lin, M., Shu, K.-H., Tung, K., Tsai, W., Yang, J., Pai, M., Wu, H., Chiu, Y., Peng, Y., et al. (2023) · American Journal of Nephrology · doi:10.1159/000529806
Raising the bar for lower-risk myelodysplastic syndromes
Venugopal, S., & Sekeres, M. A. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2197536
Effect of Roxadustat on Lipid Metabolism in Maintenance Peritoneal Dialysis Patients
周, 慧. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1351053
Zeng, L., Ng, J. K., Fung, W. W., Chan, G. C., Chow, K. M., & Szeto, C. (2023) · Advances in Biomarker Sciences and Technology · doi:10.1016/j.abst.2023.06.001
Diarylether‐Amino Acid Conjugates as New Class of Anticancer Agents
Le, T. T., Vo, V. H., Le, T. T. H., Vo, N. H. H., Le, X. L., Do, T. H. T., Vu, T. Y., Nguyen, P. H., Vo, D. D., & Le, T. T. (2023) · ChemistrySelect · doi:10.1002/slct.202301203
A Call for Universality of Blood Availability
Vijayan, A., & Ross, W. R. (2023) · Journal of Hospital and Healthcare Administration · doi:10.29011/2688-6472.000073
Roxadustat shows increases in Hb regardless of prior roxadustat use in CKD
Actor-Engel, H. S. (2023) · doi:10.55788/278c0c43
Wang, M., Zheng, G.-F., Li, M.-P., Chen, D.-Z., & Zhong, J.-J. (2023) · Research Square · doi:10.21203/rs.3.rs-3541322/v1
Dai, S., Chen, Y., Hao, C., 葛霄琳, 谢琼虹, Shang, D., & 朱彤莹 (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.20213210s1786d
Self-citationde Vasconcellos, A. B. M., Mendes, A. D. O., Filho, C. O. M., de Matos, G. M. G., Júnior, H. H. S., Urresti, L. G. G., de Paula, L. F. G., Ximenes, P. N., & Miotto, T. N. N. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024479p219
Shen, S., & Sun, J. (2024) · International Journal of Pharmacology · doi:10.3923/ijp.2024.1076.1086
Evaluation and Management of CKD
Knicely, D. H., & Thavarajah, S. (2024) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00242024
Mechanism of Action and Research Progress of Roxadustat in the Treatment of Renal Anemia
伍, 金. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151196
A case study on the first-in-class antirenal anemia drug roxadustat
Zhang, X., & You, Q. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27402-2.00021-8
Roxadustat for Anemia in a Patient with Chronic Kidney Disease Not Receiving Dialysis
Song, P., & Sun, L. N. (2025) · Springer eBooks · doi:10.1007/978-981-97-7636-8_15
Treatment of Anemia in a Patient with Chronic Kidney Disease and Cerebral Infarction
Zheng, W., Liu, D., & Liu, Z. (2025) · Springer eBooks · doi:10.1007/978-981-97-7636-8_27
Self-citationYin, Q., Liu, B., & Wang, B. (2025) · Springer eBooks · doi:10.1007/978-981-97-7636-8_33
Self-citationA Case of Cardiorenal Anemia Syndrome Complicated with Malignant Hypertension
Xu, X., Cheng, H., & Bian, W. (2025) · Springer eBooks · doi:10.1007/978-981-97-7636-8_22
Treatment of Anemia in a Multiple Myeloma Patient with Deep Vein Thrombosis in the Lower Limb
Gao, C., & Chen, X. (2025) · Springer eBooks · doi:10.1007/978-981-97-7636-8_5
Wang, F., Yan-Tu, & Wang, B. (2025) · Springer eBooks · doi:10.1007/978-981-97-7636-8_20
Zhu, H., Yang, X., & Wang, R. (2025) · Springer eBooks · doi:10.1007/978-981-97-7636-8_18
Research Progress on Roxadustat in the Treatment of Renal Anemia
郑, 雅. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.42247
Wang, Z., Wang, C., Fu, Z., Xu, L., Xu, J., Ma, H., Feng, X., Han, W., & Zhang, W. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5385773
Self-citationTu, Y., Xu, Y. H., Yao, L., Zhang, B., Yan, T., Yin, A., Zhang, X., Yang, M., Liu, J., Wang, C., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003786
Self-citationWang, X., Calucho, M., Estrada-Zuniga, C. M., Noureen, M., Gonzalez‐Cantu, H., Mossuto, S., Levi, J. N., Landry, B. N., Guo, Q., Rutherford, K. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.22.671868
Cernaro, V., Maressa, V., Gembillo, G., Geraci, G., Casuscelli, C., ROSSANO, C., Santoro, D., & Calabrese, V. (2025) · Minerva Urology and Nephrology · doi:10.23736/s2724-6051.25.06243-3
Effects of Daprodustat on Iron Metabolism in Peritoneal Dialysis Patients: An Exploratory Study
Yan, T., Sakai, Y., Kunoki, S., Hirama, A., Kashiwagi, T., & Iwabu, M. (2025) · Blood Purification · doi:10.1159/000548832
Sato, S., Hayashida, M., Yano, T., Takaki, T., Sakai, M., Sawase, K., Ishii, T., Hashiguchi, J., Maekawa, A., & Funakoshi, S. (2025) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.58.456
Ho, S., Mak, J. K. L., Cheng, F. W. T., Sing, C., Yap, D. Y. H., Sin, C., Tan, K. C. B., Li, G. H., & Cheung, C. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103619
Neat1 alleviates ischemic injury in skeletal musclesPreprint
Kim, K., Yu, T., Mun, H., Oh, D. G., Lee, S., Kim, M., Kim, J., Kang, Y., Li, J., Jang, Y. C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.08.687205
Murai, S., Kakeshita, K., Imamura, T., Koike, T., Yamazaki, H., & Kinugawa, K. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04675-2
Aigami, T., Ishigo, T., Miyao, M., Nonoyama, M., Yamashita, T., Koyama, M., Fujii, S., Yano, T., Furuhashi, M., Fukudo, M., et al. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00527-1
Yang, J., Ruan, Y., Wang, D., Fan, J., Luo, N., Chen, H., Li, X., Chen, W., & Wang, X. (2022) · Figshare · doi:10.6084/m9.figshare.26555759
Yang, J., Ruan, Y., Wang, D., Fan, J., Luo, N., Chen, H., Li, X., Chen, W., & Wang, X. (2024) · Figshare · doi:10.6084/m9.figshare.26555762
Progress in the Treatment of Renal Anemia with Traditional Chinese and Western Medicine
曲, 文. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15102782
Ye, Z., Xu, G., Zhang, H., Wang, L., Yin, A., Liu, H., Yang, X., Zhong, H., Xiong, F., Yang, Z., et al. (2025) · Kidney Diseases · doi:10.1159/000549723
Self-citationZhang, Y., Yi-da, P., Zheng, W.-Y., Wen, Q.-Q., Zhu, M., Li, H.-Y., Liang, W.-Q., Zhu, Z.-Y., Liu, B.-C., Yuan, X.-R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.14.699586
Self-citationChen, A., Chen, H., Han, S., Xu, L., Sun, Y., Zhang, J., & Liu, X. (2026) · Research Square · doi:10.21203/rs.3.rs-8294615/v1
Roxadustat for Refractory Anemia Associated to Cytomegalovirus Infection in Kidney Transplantation
Serrano, B., Villanego, F., Alonso, M., Amaro, J. M., Arnaiz, M., Vigara, L., Orellana, C., García, T., & Mazuecos, A. (2026) · Transplantation Proceedings · doi:10.1016/j.transproceed.2026.01.016
Hemoglobin clinical decision limits: Chasing the numbers
Oprea, O. R., & Preda, E. C. (2026) · Revista română de medicină de laborator · doi:10.2478/rrlm-2026-0004
Ma, Y.-Y., Zhang, C., Chen, Y., Zeng, L., & Zhang, X. (2026) · Blood Science · doi:10.1097/bs9.0000000000000281 · Cited by 1
Klemola, E., Tapio, J., Valtonen, R. I. P., Tulppo, M. P., Hukkanen, J., & Koivunen, P. (2026) · Methods and Protocols · doi:10.3390/mps9020051
Anémie à la sortie de réanimation pédiatrique : prévalence, marqueurs de risque et prise en charge
Demaret, P. (2020) · theses.fr (ABES) · doi:10.70675/9f43b8dfz2d19z4048zb4a2z2d5ac9df5190
Wang, H., Wang, Q., Liu, S., Zhang, Y., Ding, K., Li, X., Jiao, W., Zhang, Q., Fu, J., Cao, J., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02635-2
Self-citationHuang, Y.-H., Huang, Y.-H., Peng, T., & Wu, T.-W. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04072-0
Su, H., Li, Y., Xie, T., Huang, C., Liu, J. Z., Wu, A., Wang, J., Xiang, J., Liu, X., Chen, W., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03841
Anemia and Iron Deficiency in Cardio-Renal Syndromes
Kontogiorgos, I., Roumeliotis, S. K., Roumeliotis, A., & Liakopoulos, V. (2026) · Springer eBooks · doi:10.1007/978-3-032-25434-4_14
Adediran, B., Vela‐Rodríguez, C., Murthy, S., Rahman, M. M., Wierenga, R. K., Lehtiö, L., & Koski, M. K. (2026) · Scientific Reports · doi:10.1038/s41598-026-53109-y
Unmasking erythroid suppression: the hidden culprit in renal anemia pathogenesis
Yu, J., Liu, Z., Zhang, N., Zhou, G., Guo, Z., Li, X., Li, D., Qiu, S., & Wang, X. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag111
Self-citationElkoumi, O., Elkoumi, A., Elbairy, M. K., Mahmoud, M. R., & Irfan, H. (2026) · BMC Nephrology · doi:10.1186/s12882-025-04723-x
Tang, J., Yu, Z., Pan, L., Li, X., & Zhong, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1792709
Roxadustat in lupus nephritis: a novel therapeutic signal for multifactorial anaemia
Martín‐Portugués, M., Moreno‐Torres, V., Campo, P. D., Tesillano, L. M., Portolés, J. M., & Huerta, A. (2026) · Lupus Science & Medicine · doi:10.1136/lupus-2026-002146
Management der Anämie bei chronischer Nierenerkrankung
Bhandari, S., Spencer, S., & Biggar, P. H. (2026) · Nephrologie aktuell · doi:10.1055/a-2785-5702
Klemola, E., Posio, K., Karpale, M., Dimova, E. Y., Raza, G. S., Mäkelä, K. A., Nagy, I. I., Miinalainen, I., Tapio, J., & Koivunen, P. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104295
Yang, G., Wu, J., Guo, X., Shen, W., Sang, X., Gong, X., Huang, S., Zhang, J., & Zeng, F. (2026) · Cell Proliferation · doi:10.1111/cpr.70230
Ouyang, Y., Ren, H., Zhu, L., Wu, Y., Wang, Y., Fu, X., Li, X., Wang, W. L., Cen, J., Xie, J., et al. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.06.017
Self-citationFangyu, Y., & Shuangquan, K. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101472
Effect of Roxadustat on Microinflammatory Status in Patients with Chronic Kidney DiseasePreprint
Xu, Y., Ke, Y., Guo, J., Xiao, Y., Wang, Z., Guo, B., & Ma, H. (2026) · Research Square · doi:10.21203/rs.3.rs-10344523/v1
Qin, H., Qian, Q., Xu, J., Xu, Y., Wang, L., & Hu, N. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70713
The mechanism of hypoxia-inducible factor-1α in gouty nephropathy
Xiang, Y., Sheng, L., Gao, S., & Peng, J. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05315-w
Hirai, K., Morino, J., Yanai, K., Mutsuyoshi, Y., Kitano, T., Miyazawa, H., Ito, K., Masuda, T., Ookawara, S., & Morishita, Y. (2026) · Cureus · doi:10.7759/cureus.114463
Tang, H.-E., Qiu, Y.-E., Ge, R.-X., Lin, X.-J., Zhao, Q., & Liu, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1862251
Contemporary pharmacological management of anemia associated with chronic kidney disease
Saito, T., Nangaku, M., & Mimura, I. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2726516
Luo, C., Li, T., Tak, J., DeBerge, M., Tsai, K., & Eltzschig, H. K. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01339-y
Ren, X., Huang, F., & Yao, B. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100106
nakamura, K., Fujii, Y., Arai, Y., Nakagawa, S., Inoue, A., Cha, R., Sugie, K., Hayashi, K., Saito, T., Kishida, T., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177869
Huang, J., Wang, Y., Zhang, H., 王阿薇, Zhang, M., & Cao, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1916346
Editorial, A. (2026) · Nephrology and Dialysis · doi:10.28996/2618-9801-2026-3suppl-1-111
Yang, H., 徐寧馨, Wu, Y., Cheng, M., Qiu, X., Liu, S., Zhang, M., & 张敏敏 (2026) · Biomolecules · doi:10.3390/biom16101437
Mitsuboshi, S., Morizumi, M., Imai, S., Hori, S., & Kotake, K. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70516
Wei, L., 胡玉清, Lyu, Y., Qian, H., Qin, H., Wu, Y., & Zhang, X. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01656
Roxadustat Treatment After PCI Among Patients With ST-Segment Elevation Myocardial Infarction
Quan, W., Wang, Y., Zhang, M., Zhu, T., Zhu, J., Wang, X., Zhu, Z., Du, R., Ding, F., Ni, J., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.37953
Effects of clinically available HIF-PH inhibitors on retinal Vegfa transcription
Hoshino, J., Irie, K., Konishi, A., Akiyama, H., & Minamishima, Y. A. (2026) · Scientific Reports · doi:10.1038/s41598-026-73839-3
BindingDB (2022) · UC San Diego · doi:10.7270/q2280c7p
Dilek, Ö., Atayeter, C. B., YEŞİL, T. A., & Tilki, T. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147973
Metadata
- Authors
- Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., Chen, J., Luo, L., Zuo, L., Liao, Y., Liu, B.-C., Leong, R., Wang, C., Liu, C., Neff, T., Szczech, L., & Yu, K.-H. P.
- Affiliations
- Shanghai Jiao Tong University (CN)
- From the Department of Nephrology, Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (N.C.), and the Division of Nephrology, Huashan Hospital Fudan University (C.H.), Shanghai, the Department of Nephrology, People’s Hospital of Guangxi Zhuang Autonomous Region (X.P.), and the Department of Nephrology, First Affiliated Hospital of Guangxi Medical University (Y.L.), Nanning, the First Affiliated Hospital of Dalian Medical University, Dalian (H.L.), the...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-12
- Volume
- 381
- Issue
- 11
- Pages
- 1001-1010
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2963534431
- Cited by
- 582
- References
- 32
- Citations by year
- 2026: 53 · 2025: 62 · 2024: 68 · 2023: 68 · 2022: 96 · 2021: 112 · 2020: 100 · 2019: 22
- FWCI
- 58.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- FibroGen
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- roxadustat, chronic kidney disease, anemia of chronic kidney disease, HIF prolyl hydroxylase inhibitors, non-dialysis patients, hemoglobin increase, hepcidin, iron metabolism, erythropoiesis, hyperkalemia, metabolic acidosis, total cholesterol, Chinese patients, open-label extension
- MeSH terms
- Acidosis, Adult, Aged, Anemia, Cholesterol, Double-Blind Method, Female, Glycine, Hematinics, Hemoglobins, Humans, Hyperkalemia, Isoquinolines, Male, Middle Aged, Renal Insufficiency, Chronic, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
